Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lerch

Showing results (591-600 of 640) with videos related to

Pageof 64
Sort By:
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
Nature Genetics|November 29, 2005
Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome)Martin Zenker, Julia Mayerle, Markus M Lerch, et al.
BMJ Open|September 16, 2017
High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trialKatalin Márta, Anikó N Szabó, Dániel Pécsi, et al.
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
JNCI Cancer Spectrum|April 17, 2020
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic CancerUjjwal M Mahajan, Elisabetta Goni, Enno Langhoff, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
United European Gastroenterology Journal|March 28, 2017
United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)J Matthias Löhr, Enrique Dominguez-Munoz, Jonas Rosendahl, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 26, 2021
Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ RegenerationFrank Arnold, Pallavi U Mahaddalkar, Johann M Kraus, et al.
Gut|December 3, 2009
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis familiesChristopher J Grocock, Vinciane Rebours, Myriam N Delhaye, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2025
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyUjjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, et al.
Pageof 64

Showing results (591-600 of 640) with videos related to

Sort By:
Pageof 64
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
Nature Genetics|November 29, 2005
Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome)Martin Zenker, Julia Mayerle, Markus M Lerch, et al.
BMJ Open|September 16, 2017
High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trialKatalin Márta, Anikó N Szabó, Dániel Pécsi, et al.
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
JNCI Cancer Spectrum|April 17, 2020
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic CancerUjjwal M Mahajan, Elisabetta Goni, Enno Langhoff, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
United European Gastroenterology Journal|March 28, 2017
United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)J Matthias Löhr, Enrique Dominguez-Munoz, Jonas Rosendahl, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 26, 2021
Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ RegenerationFrank Arnold, Pallavi U Mahaddalkar, Johann M Kraus, et al.
Gut|December 3, 2009
The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis familiesChristopher J Grocock, Vinciane Rebours, Myriam N Delhaye, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2025
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyUjjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, et al.
Pageof 64